In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration

Drug Development and Industrial Pharmacy

Volumn 41, Issue 2, 2015, Pages 272-278

  Liu, Chunmei ^a   Shi, Jing ^b   Dai, Qingyun ^c   Yin, Xiaoxing ^d   Zhang, Xiaoyan ^e   Zheng, Aiping ^e  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b National Medical Products Administration   (China)

^c BEIJING NORMAL UNIVERSITY   (China)

^d XUZHOU MEDICAL UNIVERSITY   (China)

^e BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Ciprofloxacin liposome; Pharmacokinetics; Pulmonary administration; Pulmonary distribution; Pulmonary irritation; Release in vitro

Indexed keywords

CIPROFLOXACIN; LIPOSOME; SODIUM CHLORIDE; ANTIINFECTIVE AGENT; DRUG CARRIER;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SCREENING; DRUG SOLUBILITY; DRUG TARGETING; DRUG TISSUE LEVEL; GEL CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL FLUID; INTRAPULMONARY DRUG ADMINISTRATION; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; ULTRAVIOLET SPECTROPHOTOMETRY; ANIMAL; BIOAVAILABILITY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; PATHOLOGY; TRACHEA; WISTAR RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; DRUG CARRIERS; IN VITRO TECHNIQUES; LIPOSOMES; LUNG; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; RATS; RATS, WISTAR; TRACHEA;

EID: 84921900075     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.858740     Document Type: Article

References (21)

1. Heijerman H, Westerman E, Conway S, et al. for the consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cystic Fibrosis 2009;8:295-315.
2. Misra A, Hickey AJ, Rossi C, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011;91:71-81.
3. Adi H, Young PM, Chan H-K, et al. Co-spray-dried mannitolciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 2010;40: 239-47.
4. Saadane A, Soltys J, Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-κB activation, cytokine secretion and persistent lung inflammation. J Allergy Clin Immunol 2006;117:1163-639.
5. Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305:180-5.
6. Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 2004;24:3-4.
7. Petersen EA, Grayson JB, Hersh EM, et al. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J Antimicrob Chemother 1996;38:819-28.
8. Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296:12-25.
9. Zaru M, Mourtas S, Klepetsanis P, et al. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 2007; 67:655-66.
10. Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm 2010;387:187-98.
11. Wong JP, Yang H, Blasetti KL, et al. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Release 2003;92:265-73.
12. Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008; 127:50-8.
13. Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 2003;51:83-91.
14. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-17.
15. Desai TR, Li D, Finlay WH, Wong JP. Determination of surface free energy of interactive dry powder liposome formulations using capillary penetration technique. Colloids Surfaces B Biointerfaces 2001;22:107-13.
16. Moazeni E, Gilani1 K, Sotoudegan F, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul 2010;27:618-27.
17. Ruizhi Z, Yingjie D, Wenping S, et al. Determination of ammonium sulfate gradient of blank liposomes by conductivity. J Shenyang Pharm Univ 2008;25:967-70.
18. Colombo C, John Monhemius A, Plant JA. Platinum, palladium and rhodium release from vehicle exhaust catalysts and road dust exposed to simulated lung fluids. Ecotoxicol Environ Saf 2008;71: 722-30.
19. Son Y-J, McConville JT. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm 2009;382:15-22.
20. Liu T, Zhao X, Duan J, et al. Influence of material and configuration of microfiltration membranes on preparation of mono-ammonium glycyrrhizinate liposome by membrane extrusion method. Chin Tradit Patent Med 2008;30:185-9.
21. Blumer JL. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents 2005;26:143-7.